01 4Fumaderm
02 8Tecfidera
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2020 Revenue in Millions : 3,841
2019 Revenue in Millions : 4,433
Growth (%) : -13
Main Therapeutic Indication : Neurology
Currency : USD
2022 Revenue in Millions : 1,444
2021 Revenue in Millions : 1,952
Growth (%) : -26
Main Therapeutic Indication : Neurology
Currency : USD
2023 Revenue in Millions : 1,013
2022 Revenue in Millions : 1,444
Growth (%) : -30
Main Therapeutic Indication : Neuroscience and Mental Health
Currency : USD
2015 Revenue in Millions : 2,909
2014 Revenue in Millions : 3,638
Growth (%) : 25%
Main Therapeutic Indication : Anti-fungal
Currency : USD
2015 Revenue in Millions : 63
2014 Revenue in Millions : 51
Growth (%) : -19%
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2017 Revenue in Millions : 4,214
2016 Revenue in Millions : 3,968
Growth (%) : 6
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2016 Revenue in Millions : 3,968
2015 Revenue in Millions : 3,638
Growth (%) : 9
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2018 Revenue in Millions : 4,274
2017 Revenue in Millions : 4,214
Growth (%) : 1%
Main Therapeutic Indication : Anti-fungal
Currency : USD
2017 Revenue in Millions : 40
2016 Revenue in Millions : 46
Growth (%) : -14
Main Therapeutic Indication : Anti-Fungal
Currency : USD
2016 Revenue in Millions : 46
2015 Revenue in Millions : 51
Growth (%) : -10
LOOKING FOR A SUPPLIER?